<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Electron Physician</journal-id><journal-id journal-id-type="iso-abbrev">Electron Physician</journal-id><journal-id journal-id-type="publisher-id">Electronic physician</journal-id><journal-title-group><journal-title>Electronic Physician</journal-title></journal-title-group><issn pub-type="epub">2008-5842</issn><publisher><publisher-name>Electronic physician</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28979743</article-id><article-id pub-id-type="pmc">5614293</article-id><article-id pub-id-type="doi">10.19082/5068</article-id><article-id pub-id-type="publisher-id">epj-09-5068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Motarjemizadeh</surname><given-names>Ghader</given-names></name><xref ref-type="aff" rid="af1-epj-09-5068">1</xref></contrib><contrib contrib-type="author"><name><surname>Rajabzadeh</surname><given-names>Miaad</given-names></name><xref ref-type="aff" rid="af2-epj-09-5068">2</xref></contrib><contrib contrib-type="author"><name><surname>Aidenloo</surname><given-names>Naser Samadi</given-names></name><xref ref-type="aff" rid="af3-epj-09-5068">3</xref><xref ref-type="corresp" rid="c1-epj-09-5068"/></contrib><contrib contrib-type="author"><name><surname>Valizadeh</surname><given-names>Rohollah</given-names></name><xref ref-type="aff" rid="af4-epj-09-5068">4</xref></contrib></contrib-group><aff id="af1-epj-09-5068">
<label>1</label>M.D., Assistant Professor, Department of Ophthalmology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran</aff><aff id="af2-epj-09-5068">
<label>2</label>General Practitioner, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran</aff><aff id="af3-epj-09-5068">
<label>3</label>M.D., Associate Professor, Department of Ophthalmology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran</aff><aff id="af4-epj-09-5068">
<label>4</label>MSc Student of Epidemiology, Student Research Committee, Department of Epidemiology, Urmia University of Medical Sciences, Urmia, Iran</aff><author-notes><corresp id="c1-epj-09-5068">Corresponding author: Naser Samadi Aidenloo, Department of Ophthalmology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Tel: +98.9141454412. Fax: +98.4333469929, Email: <email>n.samadiadnl@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>01</day><month>8</month><year>2017</year></pub-date><volume>9</volume><issue>8</issue><fpage>5068</fpage><lpage>5074</lpage><history><date date-type="received"><day>01</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><sec><title>Background</title><p>Central retinal vein occlusion (CRVO), is the second-most common disorder after diabetic retinopathy that threatens the vision related to retinal vessels. One of the main reasons of vision loss is CRVO in acute and chronic forms.</p></sec><sec><title>Objective</title><p>The aim of this study was to investigate the response to intravitreal injection of triamcinolone, bevacizumab, and a combined form in patients with CRVO.</p></sec><sec><title>Methods</title><p>This study was a double-blinded randomized clinical trial conducted on patients with CRVO who were referred to the ophthalmology clinic of Urmia Imam Khomeini Hospital from May 2015 to May 2016. In total, ninety patients were divided into three groups using random numbers table. The first group received intravitreal triamcinolone acetonide (IVT) for treatment of macular edema due to CRVO, the second group received intravitreal bevacizumab (IVB) and the third group received a combination of IVT and IVB. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded and analyzed using optical coherence tomography system.</p></sec><sec><title>Results</title><p>In this study a total of 90 eyes were studied, 41 case (45.55%) were male and 49 cases (54.44%) were female. The mean age of patients was 68.41&#x000b1;8.32 years. The mean score of final visual acuity was 0.293&#x000b1;0.11 in the IVT group, 0.25&#x000b1;0.10 in the IVB group and 0.48&#x000b1;0.15 in the IVB+IVT group. The differences between groups considering final visual acuity was significant (p&#x0003c;0.001). The mean thickness of final macular was 383.33&#x000b1;97.70 micrometer in IVT group, 386.33&#x000b1;136.79 micrometers in IVB group and 307.33&#x000b1;110.79 micrometers in IVT+IVB group which were significant (p=0.014).</p></sec><sec><title>Conclusion</title><p>Using a combination of bevacizumab and triamcinolone in the treatment of central retinal vein occlusion compared with using each of them separately, had a better result and can be used as a solution in this disease.</p></sec><sec><title>Trial registration</title><p>The trial was registered at the Thai Registry of Clinical Trials (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.in.th">http://www.clinicaltrials.in.th</ext-link>) with the TCTR ID: TCTR20170612005.</p></sec><sec><title>Funding</title><p>The authors received no financial support for the research, authorship, and/or publication of this article.</p></sec></abstract><kwd-group><kwd>Bevacizumab</kwd><kwd>Intravitreal Injections</kwd><kwd>Retinal Vein Occlusion</kwd><kwd>Triamcinolone</kwd></kwd-group></article-meta></front><body><sec><title>1. Introduction</title><p>Central retinal vein occlusion (CRVO), is the second-most common disorder after diabetic retinopathy (<xref rid="b1-epj-09-5068" ref-type="bibr">1</xref>). One of the main reasons of vision loss is CRVO in acute and chronic forms. There are many risk factors associated with CRVO including age, hypertension, diabetes mellitus, retinal artery atherosclerotic changes, open-angle glaucoma and hyperopia (<xref rid="b2-epj-09-5068" ref-type="bibr">2</xref>). Its prevalence increases with age and varies from 0.1% to 5%. Visual acuity is a reflection of the severity of the disease, retinal macular hemorrhage, cystoid macular edema and ischemia (<xref rid="b3-epj-09-5068" ref-type="bibr">3</xref>). Macular edema is one of the fundamental causes of vision loss in chronic and acute CRVO as well as ischemic and non-ischemic forms (<xref rid="b4-epj-09-5068" ref-type="bibr">4</xref>). CRVO study showed that although the macular network photocoagulation decreased angiographic edema, the vision did not improve (<xref rid="b3-epj-09-5068" ref-type="bibr">3</xref>). Recently, the standard treatment for central retinal vein occlusion was limited to photocoagulation for neovascular adverse effects and there was no solution to macular edema (<xref rid="b3-epj-09-5068" ref-type="bibr">3</xref>). The main trigger for the formation of edema and macular neovascularization in patients with CRVO is the production of vascular endothelial growth factor (VEGF (caused by hypoxia, which is an angiogenic factor, causing angiogenesis and increase of vascular permeability (<xref rid="b5-epj-09-5068" ref-type="bibr">5</xref>). It has been shown that vascular endothelial growth factor increases in eyes with CRVO (<xref rid="b6-epj-09-5068" ref-type="bibr">6</xref>). Some studies, as noted, have shown that the injection IVB and injection of IVT have beneficial effects for these cases. However, due to their half-life, repeated injections are required (<xref rid="b22-epj-09-5068" ref-type="bibr">22</xref>). Studies did not have the same results on the effectiveness and safety of these therapies in CRVO, and so, this shows the importance of this study in the world. Thus, the aim of the study was to compare the effectiveness of IVT and IVB separately and combined, for the treatment of patients with CRVO, to obtain the best choice.</p></sec><sec><title>2. Material and Methods</title><p>This study was a double-blinded randomized clinical trial conducted on patients with CRVO who were referred to the ophthalmology clinic of Urmia Imam Khomeini Hospital from May 2015 through May 2016. In total, ninety patients were divided into three groups using a random numbers table. The first group received IVT 2 mg for treatment of macular edema due to CRVO, the second group received IVB 1.25 mg and the third group received a combination of IVB 1mg and IVT 1.5 mg. All injections were carried out by one ophthalmologist after prep and drape of eye if interest in the special room of eye ward. Inclusion criteria were patients with CRVO and satisfaction to participate in the study. Exclusion criteria were the need to use macular photocoagulation in the treatment process, and intravitreal injection of any drug affecting IVB and IVT. This study had some confounding factors including systemic inflammatory disorders such as autoimmune disease, systemic risk factors, such as hypertension, diabetes, systemic vascular disease, glaucoma, hypercoagulable states, dyslipidemia, and elevated plasma levels of homocysteine, concomitant ocular pathology, e.g., diabetic retinopathy or glaucoma, vitrectomy, history of cataract surgery, contraindications for bevacizumab or triamcinolone and pregnancy.</p><p>This study was approved by the Ethics Committee of Urmia University of Medical Science (ID code: IR.UMSU.REC.73950114), and the objectives of the study were explained to all participants, and all of them agreed to participate and were assured of the confidentiality of their individual information as well as the voluntary nature of participating in the study. All patients were informed about the protocol of our study and written informed consent was taken. The goals of the study were explained to all participants and all of them agreed to participate and were assured considering the confidentiality of their individual information as well as the voluntary nature of participating. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded and analyzed using optical coherence tomography (OCT). The outcomes were checked at 10 a.m., and considering the blinded nature of this study, neither participants nor analyzer, had any information about the group assigned to the patients. Of a total of 90 patients, 41 patients (45.55%) were male and 49 patients (54.44%) were female. The mean age of the patients was 68.41&#x000b1;8.32 years. The Kolmogorov Smirov was done indicating the normal distribution of the data. The data were analyzed using software SPSS version 21. All data entered into SPSS version 21 software and data as frequency (percentage) and mean &#x000b1; SD were reported. ANCOVA (Analysis of Covariance) test was used to compare three groups. Less than 0.05 was considered as the level of significance (p&#x0003c;0.05).</p></sec><sec><title>3. Results</title><p>In this study, a total of 90 eyes were studied including 30 patients in an IVT injection group, 30 patients in an IVB injection group and 30 patients in a combination of IVT and IVB injection group, 41 cases (45.55%) were male and 49 cases (54.44%) were female. The mean age of the patients was 68.41&#x000b1;8.32 years. The mean score of final visual acuity was 0.293&#x000b1;0.11 in the IVT group, 0.25&#x000b1;0.10 in the IVB group and 0.48&#x000b1;0.15 in the IVB+IVT group. The differences between groups, considering final visual acuity, was significant (p&#x0003c;0.001). The patients were followed up two times and the mean of BVA was 0.1&#x000b1;0.05 micrometer in the IVT group, 482.11&#x000b1;120.08 micrometers in the IVB group and 0.34&#x000b1;0.16 micrometers in the IVT+IVB group (<xref ref-type="table" rid="t1-epj-09-5068">Table 1</xref>). The average of baseline visual acuity was obtained as following, in the IVT group, 301&#x000b1;0.04, in the IVB group, 101&#x000b1;0.04 and in the IVT + IVB group, 501&#x000b1;0.05. The difference between the groups was not statistically significant in terms of baseline visual acuity (p=0.968) (<xref ref-type="table" rid="t2-epj-09-5068">Table 2</xref>). The mean thickness of baseline macular was 480&#x000b1;107.99 micrometer in the IVT group, 476&#x000b1;133.17 micrometers in the IVB group and 490.33&#x000b1;121.44 micrometers in the IVT+IVB group which were not significant (p=0.895) (<xref ref-type="table" rid="t2-epj-09-5068">Table 2</xref>). The average of final visual acuity was obtained as following, in the IVT group, 0.293&#x000b1;0.11, in the IVB group, 0.25&#x000b1;0.1 and in the IVT + IVB group, 0.48&#x000b1;0.15. The difference between the groups was statistically significant in terms of final visual acuity (p&#x0003c;0.001) (<xref ref-type="table" rid="t2-epj-09-5068">Table 2</xref>). The average of final macular thickness was 383.33&#x000b1;97.70 micrometers in the IVT group, 386.33&#x000b1;136.79 micrometers in the IVB group and 307.33&#x000b1;110.79 micrometers in the IVT+IVB group, which were significant (p&#x0003c;0.014) (<xref ref-type="table" rid="t2-epj-09-5068">Table 2</xref>). The improvement of final visual acuity and macular thickness compared to baseline in all three groups were shown in <xref ref-type="fig" rid="f1-epj-09-5068">Figures 1</xref> and <xref ref-type="fig" rid="f2-epj-09-5068">2</xref>.</p></sec><sec><title>4. Discussion</title><p>Results of analysis of data obtained in this study showed that intravitreal administration of a combination of IVT and IVB drugs, had a greater impact on visual acuity and CMT in the CRVO compared to each of the drugs. During the last ten years, IVT is widely used for the treatment of proliferative diseases, ocular neovascular edematous and central retinal vein occlusion (<xref rid="b29-epj-09-5068" ref-type="bibr">29</xref>). A disproportionate distribution of inflammatory cytokines and antigenic-related retinal vein occlusion has been reported (<xref rid="b30-epj-09-5068" ref-type="bibr">30</xref>) and experimental and clinical studies have showed the temporary impact of the anti-inflammatory effect of triamcinolone in the CRVO (<xref rid="b29-epj-09-5068" ref-type="bibr">29</xref>). The two main complications of IVT are the increase of intraocular pressure and cataracts caused by steroid injections (<xref rid="b31-epj-09-5068" ref-type="bibr">31</xref>&#x02013;<xref rid="b34-epj-09-5068" ref-type="bibr">34</xref>). Instead, studies of bevacizumab by Rosenfeld et al, and another researcher have showed the improved visual acuity and decrease in macular thickness, and only minor complications in patients with CRVO have demonstrated (<xref rid="b35-epj-09-5068" ref-type="bibr">35</xref>&#x02013;<xref rid="b38-epj-09-5068" ref-type="bibr">38</xref>). The rise of anti-VEGF compounds caused significant progress in the treatment of various diseases of eyes. VEGF-A has various effects on physiological and pathophysiological processes such as the vascular permeability, chemotaxis, inflammation and mythogenesis (<xref rid="b39-epj-09-5068" ref-type="bibr">39</xref>). VEGF stimulates neovascularization, and is a crucial factor for the creation of blood vessels and neuron cells (<xref rid="b40-epj-09-5068" ref-type="bibr">40</xref>). On the one hand, hypoxia and oxygen free radicals are known as agents for the stimulation of VEGF and on the other hand, there are low levels of the VEGF in the context of epithelium pigment of the retina (<xref rid="b39-epj-09-5068" ref-type="bibr">39</xref>, <xref rid="b41-epj-09-5068" ref-type="bibr">41</xref>). All VEGF isoforms are possible using bevacizumab and ranibizumab. There is evidence supporting the theory that the use of selective inhibitor of VEGF-165 isoforms can be the means for reducing the pathological effects while maintaining its normal physiological function (<xref rid="b42-epj-09-5068" ref-type="bibr">42</xref>). Thus, according to available evidence, the use of each of these treatments alone, the more probable the harms and risks can be expected for the patients. So, in this study, effects of a combination of the drugs were compared with each of these drugs alone. In the study by Ekdawi et al., the authors reported a CRVO resistant to monotherapy bevacizumab or triamcinolone which the combination therapy of triamcinolone and bevacizumab resulted in an improvement in visual acuity and central macular thickness (<xref rid="b43-epj-09-5068" ref-type="bibr">43</xref>), and this study confirmed that the two-drug treatment was better. In another study of Ehrlich et al, the authors suggested that the combination of bevacizumab and triamcinolone improves the structure outcome in patients with retinal vein occlusion, but the authors have stated that they have no priority in using a combination of the two drugs six months after treatment compared with other studies in which either of these drugs alone had been used to achieve their objective. The last part of this study was not consistent with our study, which can be due to the longer duration of follow-up, as well as the lack of monotherapy. Also, the structure of studied populations differed in the two groups that these differences can be effective (<xref rid="b44-epj-09-5068" ref-type="bibr">44</xref>). In the study of Ramazani et al., the results showed the better response to treatment in the group of IVB, so that our study showed the better response to treatment in the group of combined IVB and IVT, which was inconsistent with our results (<xref rid="b22-epj-09-5068" ref-type="bibr">22</xref>). But the results of the study of Jin et al., were consistent with our results and had the better outcome in the group of combined IVT and IVB (<xref rid="b45-epj-09-5068" ref-type="bibr">45</xref>). Wang et al., reported that there was no significant difference in terms of CRVO treatment using IVT and IVB, which was inconsistent with our results (<xref rid="b46-epj-09-5068" ref-type="bibr">46</xref>). There is still need for further studies in order to access additional information about the choice treatment for CRVO. Other limitations of the current study were the small sample of participants and performing in the single center.</p></sec><sec><title>5. Conclusions</title><p>In general it can be concluded that the combination of bevacizumab and triamcinolone had better effect in the treatment of CRVO compared to the use of them alone, and can be used as a solution in the treatment of this disease. We suggest that the solution of the bevacizumab and triamcinolone be made by pharmacology factories, but before that, future studies in a larger sample and in different populations may approve the results of our study.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors appreciate the research chancellor of Urmia University of Medical Sciences which supported this study financially. This article is obtained from a medical student thesis by Dr. Miaad Rajabzadeh (approval number 94-0-663-1815).</p></ack><fn-group><fn id="fn1-epj-09-5068"><p>iThenticate screening: June 11, 2017, English editing: July 18, 2017, Quality control: August 02, 2017</p></fn><fn id="fn2-epj-09-5068"><p><bold>Trial registration:</bold> The trial was registered at the Thai Registry of Clinical Trials (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.in.th">http://www.clinicaltrials.in.th</ext-link>) with the TCTR ID: TCTR20170612005.</p></fn><fn id="fn3-epj-09-5068"><p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn id="fn4-epj-09-5068" fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> There is no conflict of interest to be declared.</p></fn><fn id="fn5-epj-09-5068"><p><bold>Authors&#x02019; contributions:</bold> All authors contributed to this project and article equally. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-epj-09-5068"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>SL</given-names></name><name><surname>McIntosh</surname><given-names>RL</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Cheung</surname><given-names>N</given-names></name><name><surname>Kowalski</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Natural history of branch retinal vein occlusion: an evidence-based systematic review</article-title><source>Ophthalmology</source><year>2010</year><volume>117</volume><issue>6</issue><fpage>1094</fpage><lpage>1101.e5</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2010.01.058</pub-id><pub-id pub-id-type="pmid">20430447</pub-id></element-citation></ref><ref id="b2-epj-09-5068"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name><name><surname>Meuer</surname><given-names>SM</given-names></name></person-group><article-title>The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study</article-title><source>Trans Am Ophthalmol Soc</source><year>2000</year><volume>98</volume><fpage>133</fpage><lpage>41</lpage><!--<pub-id pub-id-type="pmcid">PMC1298220</pub-id>--><pub-id pub-id-type="pmid">11190017</pub-id></element-citation></ref><ref id="b3-epj-09-5068"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAllister</surname><given-names>IL</given-names></name></person-group><article-title>Central retinal vein occlusion: a review</article-title><source>Clin Exp Ophthalmol</source><year>2012</year><volume>40</volume><issue>1</issue><fpage>48</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/j.1442-9071.2011.02713.x</pub-id><pub-id pub-id-type="pmid">22003973</pub-id></element-citation></ref><ref id="b4-epj-09-5068"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coscas</surname><given-names>G</given-names></name><name><surname>Loewenstein</surname><given-names>A</given-names></name><name><surname>Augustin</surname><given-names>A</given-names></name><name><surname>Bandello</surname><given-names>F</given-names></name><name><surname>Battaglia Parodi</surname><given-names>M</given-names></name><name><surname>Lanzetta</surname><given-names>P</given-names></name><etal/></person-group><article-title>Management of retinal vein occlusion--consensus document</article-title><source>Ophthalmologica</source><year>2011</year><volume>226</volume><issue>1</issue><fpage>4</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">21577038</pub-id></element-citation></ref><ref id="b5-epj-09-5068"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Avery</surname><given-names>RL</given-names></name><name><surname>Arrigg</surname><given-names>PG</given-names></name><name><surname>Keyt</surname><given-names>BA</given-names></name><name><surname>Jampel</surname><given-names>HD</given-names></name><name><surname>Shah</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><issue>22</issue><fpage>1480</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1056/NEJM199412013312203</pub-id><pub-id pub-id-type="pmid">7526212</pub-id></element-citation></ref><ref id="b6-epj-09-5068"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pe&#x02019;er</surname><given-names>J</given-names></name><name><surname>Folberg</surname><given-names>R</given-names></name><name><surname>Itin</surname><given-names>A</given-names></name><name><surname>Gnessin</surname><given-names>H</given-names></name><name><surname>Hemo</surname><given-names>I</given-names></name><name><surname>Keshet</surname><given-names>E</given-names></name></person-group><article-title>Vascular endothelial growth factor upregulation in human central retinal vein occlusion</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><issue>3</issue><fpage>412</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(98)93020-2</pub-id><pub-id pub-id-type="pmid">9499769</pub-id></element-citation></ref><ref id="b7-epj-09-5068"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>EW</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name></person-group><article-title>Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration</article-title><source>Can J Ophthalmol</source><year>2005</year><volume>40</volume><issue>3</issue><fpage>352</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/S0008-4182(05)80078-X</pub-id><pub-id pub-id-type="pmid">15947805</pub-id></element-citation></ref><ref id="b8-epj-09-5068"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noma</surname><given-names>H</given-names></name><name><surname>Minamoto</surname><given-names>A</given-names></name><name><surname>Funatsu</surname><given-names>H</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><etal/></person-group><article-title>Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2006</year><volume>244</volume><issue>3</issue><fpage>309</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s00417-004-1087-4</pub-id><pub-id pub-id-type="pmid">16133018</pub-id></element-citation></ref><ref id="b9-epj-09-5068"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>CA</given-names></name><name><surname>Berkowitz</surname><given-names>BA</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Ando</surname><given-names>N</given-names></name><name><surname>Handa</surname><given-names>JT</given-names></name><name><surname>de Juan</surname><given-names>E</given-names><suffix>Jr</suffix></name></person-group><article-title>Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation</article-title><source>Arch Ophthalmol</source><year>1992</year><volume>110</volume><issue>8</issue><fpage>1155</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1497531</pub-id></element-citation></ref><ref id="b10-epj-09-5068"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezatis</surname><given-names>A</given-names></name><name><surname>Spital</surname><given-names>G</given-names></name><name><surname>Hohn</surname><given-names>F</given-names></name><name><surname>Maier</surname><given-names>M</given-names></name><name><surname>Clemens</surname><given-names>CR</given-names></name><name><surname>Wachtlin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up -- the SOLO study</article-title><source>Acta Ophthalmol</source><year>2013</year><volume>91</volume><issue>5</issue><fpage>e340</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/aos.12020</pub-id><pub-id pub-id-type="pmid">23638803</pub-id></element-citation></ref><ref id="b11-epj-09-5068"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>L</given-names></name><name><surname>Tomkins-Netzer</surname><given-names>O</given-names></name><name><surname>Menezo</surname><given-names>V</given-names></name><name><surname>Sallam</surname><given-names>A</given-names></name><name><surname>Kirkpatrick</surname><given-names>N</given-names></name><name><surname>Lightman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dexamethasone implants and neovascular glaucoma in central retinal vein occlusion</article-title><source>Acta Ophthalmol</source><year>2013</year><volume>91</volume><issue>3</issue><fpage>e239</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/aos.12009</pub-id><pub-id pub-id-type="pmid">23241218</pub-id></element-citation></ref><ref id="b12-epj-09-5068"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matonti</surname><given-names>F</given-names></name><name><surname>Meyer</surname><given-names>F</given-names></name><name><surname>Guigou</surname><given-names>S</given-names></name><name><surname>Barthelemy</surname><given-names>T</given-names></name><name><surname>Dumas</surname><given-names>S</given-names></name><name><surname>Gobert</surname><given-names>F</given-names></name><etal/></person-group><article-title>Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice</article-title><source>Acta Ophthalmol</source><year>2013</year><volume>91</volume><issue>7</issue><fpage>e584</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/aos.12190</pub-id><pub-id pub-id-type="pmid">23764276</pub-id></element-citation></ref><ref id="b13-epj-09-5068"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Karakiulakis</surname><given-names>G</given-names></name><name><surname>Perruchoud</surname><given-names>AP</given-names></name><name><surname>Papakonstantinou</surname><given-names>E</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells</article-title><source>Eur J Pharmacol</source><year>1998</year><volume>341</volume><issue>2&#x02013;3</issue><fpage>309</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9543253</pub-id></element-citation></ref><ref id="b14-epj-09-5068"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Entezari</surname><given-names>M</given-names></name><name><surname>Moradian</surname><given-names>S</given-names></name><name><surname>Tabatabaei</surname><given-names>H</given-names></name><name><surname>Kadkhodaei</surname><given-names>S</given-names></name></person-group><article-title>Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2006</year><volume>244</volume><issue>12</issue><fpage>1601</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s00417-006-0348-9</pub-id><pub-id pub-id-type="pmid">16738858</pub-id></element-citation></ref><ref id="b15-epj-09-5068"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>MS</given-names></name><name><surname>Scott</surname><given-names>IU</given-names></name><name><surname>VanVeldhuisen</surname><given-names>PC</given-names></name><name><surname>Oden</surname><given-names>NL</given-names></name><name><surname>Blodi</surname><given-names>BA</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5</article-title><source>Arch Ophthalmol</source><year>2009</year><volume>127</volume><issue>9</issue><fpage>1101</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1001/archophthalmol.2009.234</pub-id><!--<pub-id pub-id-type="pmcid">PMC2872173</pub-id>--><pub-id pub-id-type="pmid">19752419</pub-id></element-citation></ref><ref id="b16-epj-09-5068"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Algvere</surname><given-names>PV</given-names></name><name><surname>Epstein</surname><given-names>D</given-names></name><name><surname>von Wendt</surname><given-names>G</given-names></name><name><surname>Seregard</surname><given-names>S</given-names></name><name><surname>Kvanta</surname><given-names>A</given-names></name></person-group><article-title>Intravitreal bevacizumab in central retinal vein occlusion: 18&#x02013;month results of a prospective clinical trial</article-title><source>Eur J Ophthalmol</source><year>2011</year><volume>21</volume><issue>6</issue><fpage>789</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.5301/EJO.2011.6522</pub-id><pub-id pub-id-type="pmid">21484753</pub-id></element-citation></ref><ref id="b17-epj-09-5068"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname><given-names>PA</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Awh</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Gray</surname><given-names>S</given-names></name><name><surname>Saroj</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study</article-title><source>Ophthalmology</source><year>2011</year><volume>118</volume><issue>10</issue><fpage>2041</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.02.038</pub-id><pub-id pub-id-type="pmid">21715011</pub-id></element-citation></ref><ref id="b18-epj-09-5068"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>DL</given-names></name><name><surname>Algvere</surname><given-names>PV</given-names></name><name><surname>von Wendt</surname><given-names>G</given-names></name><name><surname>Seregard</surname><given-names>S</given-names></name><name><surname>Kvanta</surname><given-names>A</given-names></name></person-group><article-title>Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><issue>6</issue><fpage>1184</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.01.022</pub-id><pub-id pub-id-type="pmid">22424833</pub-id></element-citation></ref><ref id="b19-epj-09-5068"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Campochiaro</surname><given-names>PA</given-names></name><name><surname>Yau</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Saroj</surname><given-names>N</given-names></name><name><surname>Rubio</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><issue>4</issue><fpage>802</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2011.12.005</pub-id><pub-id pub-id-type="pmid">22301066</pub-id></element-citation></ref><ref id="b20-epj-09-5068"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>R</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>Suner</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>CM</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><issue>10</issue><fpage>2108</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.05.017</pub-id><pub-id pub-id-type="pmid">22817833</pub-id></element-citation></ref><ref id="b21-epj-09-5068"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>ZL</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name></person-group><article-title>Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial</article-title><source>J Ocul Pharmacol Ther</source><year>2011</year><volume>27</volume><issue>6</issue><fpage>615</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1089/jop.2011.0050</pub-id><pub-id pub-id-type="pmid">21823986</pub-id></element-citation></ref><ref id="b22-epj-09-5068"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Esfandiari</surname><given-names>H</given-names></name><name><surname>Entezari</surname><given-names>M</given-names></name><name><surname>Moradian</surname><given-names>S</given-names></name><name><surname>Soheilian</surname><given-names>M</given-names></name><name><surname>Dehsarvi</surname><given-names>B</given-names></name><etal/></person-group><article-title>Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion</article-title><source>Acta Ophthalmol</source><year>2014</year><volume>92</volume><issue>7</issue><fpage>e530</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/aos.12317</pub-id><pub-id pub-id-type="pmid">24373344</pub-id></element-citation></ref><ref id="b23-epj-09-5068"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelghany</surname><given-names>AI</given-names></name><name><surname>Mahmoud</surname><given-names>M</given-names></name><name><surname>Alazab</surname><given-names>EA</given-names></name><name><surname>Ghazy</surname><given-names>MI</given-names></name><name><surname>Abdallah</surname><given-names>MA</given-names></name></person-group><article-title>Prospective study of single intravitreal triamcinolone acetonide versus bevacizumab for treatment macular edema secondary to branch retinal vein occlusion</article-title><source>AAMJ</source><year>2011</year><volume>9</volume><issue>2</issue><fpage>68</fpage><lpage>80</lpage></element-citation></ref><ref id="b24-epj-09-5068"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priglinger</surname><given-names>SG</given-names></name><name><surname>Wolf</surname><given-names>AH</given-names></name><name><surname>Kreutzer</surname><given-names>TC</given-names></name><name><surname>Kook</surname><given-names>D</given-names></name><name><surname>Hofer</surname><given-names>A</given-names></name><name><surname>Strauss</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial</article-title><source>Retina</source><year>2007</year><volume>27</volume><issue>8</issue><fpage>1004</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e3180ed458d</pub-id><pub-id pub-id-type="pmid">18040236</pub-id></element-citation></ref><ref id="b25-epj-09-5068"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astam</surname><given-names>N</given-names></name><name><surname>Batioglu</surname><given-names>F</given-names></name><name><surname>Ozmert</surname><given-names>E</given-names></name></person-group><article-title>Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion</article-title><source>Int Ophthalmol</source><year>2009</year><volume>29</volume><issue>5</issue><fpage>343</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10792-008-9242-2</pub-id><pub-id pub-id-type="pmid">18553061</pub-id></element-citation></ref><ref id="b26-epj-09-5068"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>RA</given-names></name><name><surname>Jorge</surname><given-names>R</given-names></name><name><surname>Calucci</surname><given-names>D</given-names></name><name><surname>Melo</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name><surname>Cardillo</surname><given-names>JA</given-names></name><name><surname>Scott</surname><given-names>IU</given-names></name></person-group><article-title>Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study</article-title><source>Retina</source><year>2007</year><volume>27</volume><issue>2</issue><fpage>141</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e31802eff83</pub-id><pub-id pub-id-type="pmid">17290194</pub-id></element-citation></ref><ref id="b27-epj-09-5068"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badala</surname><given-names>F</given-names></name></person-group><article-title>The treatment of branch retinal vein occlusion with bevacizumab</article-title><source>Curr Opin Ophthalmol</source><year>2008</year><volume>19</volume><issue>3</issue><fpage>234</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/ICU.0b013e3282fb7fb0</pub-id><pub-id pub-id-type="pmid">18408499</pub-id></element-citation></ref><ref id="b28-epj-09-5068"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soheilian</surname><given-names>M</given-names></name><name><surname>Ramezani</surname><given-names>A</given-names></name><name><surname>Bijanzadeh</surname><given-names>B</given-names></name><name><surname>Yaseri</surname><given-names>M</given-names></name><name><surname>Ahmadieh</surname><given-names>H</given-names></name><name><surname>Dehghan</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema</article-title><source>Retina</source><year>2007</year><volume>27</volume><issue>9</issue><fpage>1187</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e31815ec261</pub-id><pub-id pub-id-type="pmid">18046223</pub-id></element-citation></ref><ref id="b29-epj-09-5068"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>YR</given-names></name><name><surname>Li</surname><given-names>XX</given-names></name><name><surname>Jonas</surname><given-names>JB</given-names></name></person-group><article-title>Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion</article-title><source>Eye (Lond)</source><year>2010</year><volume>24</volume><issue>5</issue><fpage>810</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/eye.2009.220</pub-id><pub-id pub-id-type="pmid">19696805</pub-id></element-citation></ref><ref id="b30-epj-09-5068"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noma</surname><given-names>H</given-names></name><name><surname>Funatsu</surname><given-names>H</given-names></name><name><surname>Yamasaki</surname><given-names>M</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name><name><surname>Mimura</surname><given-names>T</given-names></name><name><surname>Sone</surname><given-names>T</given-names></name><etal/></person-group><article-title>Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>140</volume><issue>2</issue><fpage>256</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2005.03.003</pub-id><pub-id pub-id-type="pmid">16086947</pub-id></element-citation></ref><ref id="b31-epj-09-5068"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>MC</given-names></name><name><surname>Simpson</surname><given-names>JM</given-names></name><name><surname>Billson</surname><given-names>FA</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Penfold</surname><given-names>P</given-names></name><name><surname>Chua</surname><given-names>W</given-names></name><etal/></person-group><article-title>Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial</article-title><source>Arch Ophthalmol</source><year>2004</year><volume>122</volume><issue>3</issue><fpage>336</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1001/archopht.122.3.336</pub-id><pub-id pub-id-type="pmid">15006845</pub-id></element-citation></ref><ref id="b32-epj-09-5068"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Kreissig</surname><given-names>I</given-names></name><name><surname>Degenring</surname><given-names>R</given-names></name></person-group><article-title>Intraocular pressure after intravitreal injection of triamcinolone acetonide</article-title><source>Br J Ophthalmol</source><year>2003</year><volume>87</volume><issue>1</issue><fpage>24</fpage><lpage>7</lpage><!--<pub-id pub-id-type="pmcid">PMC1771462</pub-id>--><pub-id pub-id-type="pmid">12488256</pub-id></element-citation></ref><ref id="b33-epj-09-5068"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>LI</given-names></name><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Lee</surname><given-names>FL</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Ko</surname><given-names>YC</given-names></name><name><surname>Liu</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>146</volume><issue>4</issue><fpage>573</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2008.05.034</pub-id><pub-id pub-id-type="pmid">18639860</pub-id></element-citation></ref><ref id="b34-epj-09-5068"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smithen</surname><given-names>LM</given-names></name><name><surname>Ober</surname><given-names>MD</given-names></name><name><surname>Maranan</surname><given-names>L</given-names></name><name><surname>Spaide</surname><given-names>RF</given-names></name></person-group><article-title>Intravitreal triamcinolone acetonide and intraocular pressure</article-title><source>Am J Ophthalmol</source><year>2004</year><volume>138</volume><issue>5</issue><fpage>740</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2004.06.067</pub-id><pub-id pub-id-type="pmid">15531307</pub-id></element-citation></ref><ref id="b35-epj-09-5068"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>RS</given-names></name><name><surname>Sivalingam</surname><given-names>A</given-names></name><name><surname>Abraham</surname><given-names>P</given-names></name><name><surname>Fineman</surname><given-names>MS</given-names></name><name><surname>Samuel</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Intravitreal bevacizumab (avastin) in central retinal vein occlusion</article-title><source>Retina</source><year>2007</year><volume>27</volume><issue>8</issue><fpage>1013</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/IAE.0b013e318050ca7c</pub-id><pub-id pub-id-type="pmid">18040237</pub-id></element-citation></ref><ref id="b36-epj-09-5068"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iturralde</surname><given-names>D</given-names></name><name><surname>Spaide</surname><given-names>RF</given-names></name><name><surname>Meyerle</surname><given-names>CB</given-names></name><name><surname>Klancnik</surname><given-names>JM</given-names></name><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Fisher</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study</article-title><source>Retina</source><year>2006</year><volume>26</volume><issue>3</issue><fpage>279</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16508427</pub-id></element-citation></ref><ref id="b37-epj-09-5068"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>PJ</given-names></name><name><surname>Fung</surname><given-names>AE</given-names></name><name><surname>Puliafito</surname><given-names>CA</given-names></name></person-group><article-title>Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion</article-title><source>Ophthalmic Surg Lasers Imaging</source><year>2005</year><volume>36</volume><issue>4</issue><fpage>336</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16156153</pub-id></element-citation></ref><ref id="b38-epj-09-5068"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spandau</surname><given-names>UH</given-names></name><name><surname>Ihloff</surname><given-names>AK</given-names></name><name><surname>Jonas</surname><given-names>JB</given-names></name></person-group><article-title>Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion</article-title><source>Acta Ophthalmol Scand</source><year>2006</year><volume>84</volume><issue>4</issue><fpage>555</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0420.2006.00740.x</pub-id><pub-id pub-id-type="pmid">16879582</pub-id></element-citation></ref><ref id="b39-epj-09-5068"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhisitkul</surname><given-names>RB</given-names></name></person-group><article-title>Vascular endothelial growth factor biology: clinical implications for ocular treatments</article-title><source>Br J Ophthalmol</source><year>2006</year><volume>90</volume><issue>12</issue><fpage>1542</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1136/bjo.2006.098426</pub-id><!--<pub-id pub-id-type="pmcid">PMC1857529</pub-id>--><pub-id pub-id-type="pmid">17114590</pub-id></element-citation></ref><ref id="b40-epj-09-5068"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>MC</given-names></name></person-group><article-title>What we don&#x02019;t know about avastin might hurt us</article-title><source>Arch Ophthalmol</source><year>2006</year><volume>124</volume><issue>10</issue><fpage>1478</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archopht.124.10.1478</pub-id><pub-id pub-id-type="pmid">17030717</pub-id></element-citation></ref><ref id="b41-epj-09-5068"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlingemann</surname><given-names>RO</given-names></name></person-group><article-title>Role of growth factors and the wound healing response in age-related macular degeneration</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2004</year><volume>242</volume><issue>1</issue><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1007/s00417-003-0828-0</pub-id><pub-id pub-id-type="pmid">14685874</pub-id></element-citation></ref><ref id="b42-epj-09-5068"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Altaweel</surname><given-names>M</given-names></name><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><issue>10</issue><fpage>1747</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2005.06.007</pub-id><pub-id pub-id-type="pmid">16154196</pub-id></element-citation></ref><ref id="b43-epj-09-5068"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekdawi</surname><given-names>NS</given-names></name><name><surname>Bakri</surname><given-names>SJ</given-names></name></person-group><article-title>Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone</article-title><source>Eye (Lond)</source><year>2007</year><volume>21</volume><issue>8</issue><fpage>1128</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/sj.eye.6702903</pub-id><pub-id pub-id-type="pmid">17585312</pub-id></element-citation></ref><ref id="b44-epj-09-5068"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrlich</surname><given-names>R</given-names></name><name><surname>Ciulla</surname><given-names>TA</given-names></name><name><surname>Moss</surname><given-names>AM</given-names></name><name><surname>Harris</surname><given-names>A</given-names></name></person-group><article-title>Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2010</year><volume>248</volume><issue>3</issue><fpage>375</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s00417-009-1211-6</pub-id><pub-id pub-id-type="pmid">19898827</pub-id></element-citation></ref><ref id="b45-epj-09-5068"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>E</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><article-title>Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema</article-title><source>Ann Pharmacother</source><year>2015</year><volume>49</volume><issue>4</issue><fpage>387</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1177/1060028014568006</pub-id><pub-id pub-id-type="pmid">25622852</pub-id></element-citation></ref><ref id="b46-epj-09-5068"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>YS</given-names></name><name><surname>Zhang</surname><given-names>ZF</given-names></name><name><surname>Li</surname><given-names>MH</given-names></name><name><surname>Su</surname><given-names>XN</given-names></name><etal/></person-group><article-title>Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion</article-title><source>Int J Ophthalmol</source><year>2011</year><volume>4</volume><issue>1</issue><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3980/j.issn.2222-3959.2011.01.21</pub-id><!--<pub-id pub-id-type="pmcid">PMC3340676</pub-id>--><pub-id pub-id-type="pmid">22553618</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-epj-09-5068" position="float"><label>Figure 1</label><caption><p>Comparison of improvement rate of visual acuity in the three groups</p></caption><graphic xlink:href="EPJ-09-5068-g001"/></fig><fig id="f2-epj-09-5068" position="float"><label>Figure 2</label><caption><p>Comparison of improvement rate of macular thickness in the three groups.</p></caption><graphic xlink:href="EPJ-09-5068-g002"/></fig><table-wrap id="t1-epj-09-5068" position="float"><label>Table 1</label><caption><p>Average of baseline and final of visual acuity and macular thickness in the three groups.</p></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Mean</th><th valign="top" align="left" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline visual acuity</td><td valign="top" align="left" rowspan="1" colspan="1">0.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline macular thickness</td><td valign="top" align="left" rowspan="1" colspan="1">482.11</td><td valign="top" align="left" rowspan="1" colspan="1">120.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Final visual acuity</td><td valign="top" align="left" rowspan="1" colspan="1">0.34</td><td valign="top" align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Final macular thickness</td><td valign="top" align="left" rowspan="1" colspan="1">359</td><td valign="top" align="left" rowspan="1" colspan="1">120.66</td></tr></tbody></table></table-wrap><table-wrap id="t2-epj-09-5068" position="float"><label>Table 2</label><caption><p>Average of baseline visual acuity, baseline macular thickness, final visual acuity and final macular thickness in the three groups.</p></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Group</th><th colspan="2" valign="top" align="left" rowspan="1">baseline visual acuity</th><th colspan="2" valign="top" align="left" rowspan="1">baseline macular thickness</th><th colspan="2" valign="top" align="left" rowspan="1">final visual acuity</th><th colspan="2" valign="top" align="left" rowspan="1">final macular thickness</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">IVT</td><td valign="top" align="left" rowspan="1" colspan="1">0.103 (0.04)</td><td rowspan="3" valign="top" align="left" colspan="1">0.968</td><td valign="top" align="left" rowspan="1" colspan="1">480 (107.99)</td><td rowspan="3" valign="top" align="left" colspan="1">0.895</td><td valign="top" align="left" rowspan="1" colspan="1">0.293 (0.11)</td><td rowspan="3" valign="top" align="left" colspan="1">&#x0003c; 0.001</td><td valign="top" align="left" rowspan="1" colspan="1">383.33 (97.70)</td><td rowspan="3" valign="top" align="left" colspan="1">0.014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IVB</td><td valign="top" align="left" rowspan="1" colspan="1">0.101 (0.04)</td><td valign="top" align="left" rowspan="1" colspan="1">476 (133.17)</td><td valign="top" align="left" rowspan="1" colspan="1">0.25 (0.1)</td><td valign="top" align="left" rowspan="1" colspan="1">386.33 (136.79)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IVB+IVT</td><td valign="top" align="left" rowspan="1" colspan="1">0.105 (0.05)</td><td valign="top" align="left" rowspan="1" colspan="1">490.33 (121.44)</td><td valign="top" align="left" rowspan="1" colspan="1">0.48 (0.15)</td><td valign="top" align="left" rowspan="1" colspan="1">307.33 (110.79)</td></tr></tbody></table></table-wrap></floats-group></article>